HTR2A and glioma: To advance clinical translation, we next tested the effects of an FDA-approved 5HT2A inverse agonist (pimavanserin) on glioma proliferation rates and overall survival in models of DMG in the ventral pons or GBM in the cortex without optogenetic stimulation (Fig. 4L).